Financial Ratios

BAFNA PHARMACEUTICALS LTD.

NSE : BAFNAPHBSE : 532989ISIN CODE : INE878I01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE76.66-0.83 (-1.07 %)
PREV CLOSE ( ) 77.49
OPEN PRICE ( ) 77.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 446
TODAY'S LOW / HIGH ( )76.50 78.00
52 WK LOW / HIGH ( )76.5 125.55
NSE78.350.3 (+0.38 %)
PREV CLOSE( ) 78.05
OPEN PRICE ( ) 76.20
BID PRICE (QTY) 78.35 (10)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 23233
TODAY'S LOW / HIGH( ) 75.90 78.70
52 WK LOW / HIGH ( )75.9 124.45
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)4.792.212.46-7.94-8.34
   CEPS(Rs)7.054.534.365.87-6.89
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)31.0526.1924.00-18.648.79
   Tax Rate(%)2.400.000.000.00-8.23
Margin Ratios
   Core EBITDA Margin(%)13.6213.9814.462.89-29.95
   EBIT Margin(%)11.847.069.22-4.20-36.91
   Pre Tax Margin(%)10.076.138.18-4.42-41.79
   PAT Margin (%)9.836.138.18-4.42-45.23
   Cash Profit Margin (%)14.4512.5814.473.27-37.38
Performance Ratios
   ROA(%)10.325.917.40-1.96-15.90
   ROE(%)16.758.7922.26-22.93-64.36
   ROCE(%)16.128.4210.62-2.95-20.90
   Asset Turnover(x)1.050.960.900.440.35
   Sales/Fixed Asset(x)1.261.020.930.580.60
   Working Capital/Sales(x)2.822.952.812.26-1.95
Efficiency Ratios
   Fixed Capital/Sales(x)0.790.981.081.731.67
   Receivable days88.4952.1739.96132.64205.45
   Inventory Days67.2476.5768.8288.9283.48
   Payable days118.26105.56133.55586.42512.64
Valuation Parameters
   PER(x)17.2457.5955.740.000.00
   PCE(x)11.7328.0531.521.51-1.59
   Price/Book(x)2.664.855.72-0.481.25
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)1.833.664.72-0.081.59
   EV/Core EBITDA(x)11.0922.7930.42-2.27-5.47
   EV/EBIT(x)15.4351.8051.151.89-4.31
   EV/CE(x)1.633.453.89-0.050.58
   M Cap / Sales1.703.534.560.050.59
Growth Ratio
   Net Sales Growth(%)35.4819.5567.68-2.65-7.51
   Core EBITDA Growth(%)39.0023.66644.34111.70-231.59
   EBIT Growth(%)127.17-8.50468.5088.93-115.56
   PAT Growth(%)117.34-10.47410.2690.48-19.94
   EPS Growth(%)117.34-10.47131.034.82-19.94
Financial Stability Ratios
   Total Debt/Equity(x)0.310.180.23-0.682.22
   Current Ratio(x)1.882.312.042.100.68
   Quick Ratio(x)1.401.391.411.430.55
   Interest Cover(x)6.707.578.85-18.66-7.57
   Total Debt/Mcap(x)0.120.040.041.441.78

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.